Chiara Ambrogio

Company: University of Turin

Job title: Molecular Biotechnology Center

Seminars:

Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms 9:00 am

• What is the scope for pan-RAS beyond canonical RAS isoforms? • What is the scope for targeting patient populations with NRAS isoforms? Can go as far as drugging melanoma? • What combination therapies should be deployed with pan-RAS and how can we inform this? Read more

day: Day One

Debunking Safety & Efficacy Concerns Surrounding Targeting Wild Type KRAS to Induced Tumor Regression 8:30 am

Wild type KRAS continues to present a huge challenge in selectively targeting mutant variants implicated in cancer due to its structural similarity and essential cellular functions. Debate surrounds the feasibility and safety of directly targeting wild type KRAS, with concerns over potential off-target effects. Despite advances in structural and functional studies, these findings are yet…Read more

day: Workshop A